Tirzepatide's Effects on Epigenetic Aging and Metabolic Restoration in Virally Suppressed People With HIV
- Status
- Enrolling by invitationResults none
- Why it is watched
- non-weight indication: aging, other_emerging
- Who it enrolls
- age 18 Years to no upper limit; BMI ≥30 required; conditions: Human Immunodeficiency Virus (HIV); Metabolic Dysfunction Associated Steatotic Liver Disease; Dyslipidaemia; Diabetes Mellitus
- Interventions
- Tirzepatide
- Conditions
- Human Immunodeficiency Virus (HIV); Metabolic Dysfunction Associated Steatotic Liver Disease; Dyslipidaemia; Diabetes Mellitus; Obesity & Overweight; Metabolic Syndrome
- Phase and size
- Phase 4 · 60 participants
- Dates
- Start 2026-06-25
Primary completion 2027-12 - Sponsor
- National Taiwan University Clinical Trial Center (Other)
- Last checked
- Sep 13, 2026
01Endpoints
What the trial will measure
- Second generation epigenetic aging clockBaseline, week 33, week 57
- Third generation epigenetic aging clockBaseline, week 33, week 57
02Eligibility
Who can take part
Inclusion Criteria: \- Adult people living with HIV, who are virally suppressed, defined as plasma HIV viral load is \< 200 copies/mL within 6 months before enrollment. Participants have to have BMI \> 30 kg/m2. Exclusion Criteria: * Participants cannot have undergone treatment with any incretin-based treatment within the past 90 days before enrollment. Participants cannot have any AIDS-defining illnesses, active malignancy, or history of decompensated liver failure. Participants cannot be pregnant. Participants cannot have history of acute pancreatitis or a family history of medullary thyroid cancer.
03Change log
Registry changes
No changes recorded since the trial was added.